Dimerix Limited ( (AU:DXB) ) just unveiled an announcement.
Dimerix Limited has announced the application for quotation of 98,301 fully paid ordinary securities on the Australian Securities Exchange (ASX), effective from March 25, 2025. This move reflects the company’s ongoing efforts to enhance its financial flexibility and potentially strengthen its market position by increasing its capital base, which could have implications for its growth strategy and stakeholder interests.
More about Dimerix Limited
Dimerix Limited operates in the biotechnology industry, focusing on developing innovative therapies for unmet medical needs. The company is known for its work in drug discovery and development, particularly in areas such as kidney disease and other chronic conditions.
YTD Price Performance: 39.71%
Average Trading Volume: 2,432,309
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$265.6M
See more data about DXB stock on TipRanks’ Stock Analysis page.